Avoro Capital Advisors LLC
Institutional investor · Portfolio as of Q4 2022
Top Holdings36 positions
Stock | Shares | Value | Weight | Avg Buy | Est. P&L | Held | Conviction |
|---|---|---|---|---|---|---|---|
UNITED THERAPEUTICS CORP | 2.9M | $796.7M | 11.9% | $150.28 | +85.05% | 9 qtrssince 2020-Q4 | Decreased 0 |
HORIZON THERAPEUTICS PLC | 7M | $796.6M | 11.9% | — | — | 15 qtrssince 2019-Q2 | Increased 81 |
APELLIS PHARMACEUTICALS INC | 10.6M | $549.4M | 8.2% | $42.87 | +20.62% | 8 qtrssince 2021-Q1 | Increased 65 |
MADRIGAL PHARMACEUTICALS INC | 1.7M | $481.8M | 7.2% | $127.67 | +127.35% | 16 qtrssince 2019-Q1 | Increased 67 |
ARGENX SE - ADR | 1.3M | $479.4M | 7.2% | $184.45 | +105.39% | 16 qtrssince 2019-Q1 | Unchanged 0 |
AVI BIOPHARMA INC | 3.2M | $411.4M | 6.1% | $102.36 | +26.59% | 16 qtrssince 2019-Q1 | Unchanged 0 |
ASCENDIS PHARMA A/S | 3.1M | $378.6M | 5.7% | $125.87 | -2.97% | 7 qtrssince 2021-Q2 | Increased 67 |
BIOMARIN PHARMACEUTICAL INC | 3.6M | $368M | 5.5% | $84.92 | +21.87% | 16 qtrssince 2019-Q1 | Unchanged 0 |
AMICUS THERAPEUTICS INC | 26.8M | $327.2M | 4.9% | $11.07 | +10.34% | 16 qtrssince 2019-Q1 | Unchanged 0 |
ALNYLAM PHARMACEUTICALS INC | 1.1M | $262.6M | 3.9% | $165.72 | +43.41% | 7 qtrssince 2021-Q2 | Unchanged 0 |
MIRATI THERAPEUTICS INC | 5.6M | $251.7M | 3.8% | — | — | 16 qtrssince 2019-Q1 | Increased 57 |
SEAGEN INC | 1.9M | $242.2M | 3.6% | — | — | 4 qtrssince 2022-Q1 | Increased 58 |
XENON PHARMACEUTICALS INC | 4.9M | $193.2M | 2.9% | $17.33 | +127.58% | 16 qtrssince 2019-Q1 | Unchanged 0 |
IVERIC BIO INC | 6.8M | $144.5M | 2.2% | — | — | 11 qtrssince 2020-Q2 | Increased 60 |
Krystal Biotech, Inc. | 1.4M | $111.7M | 1.7% | $69.70 | +13.66% | 5 qtrssince 2021-Q4 | Increased 53 |
BIOCRYST PHARMACEUTICALS INC | 9.1M | $103.9M | 1.6% | $12.41 | -7.52% | 4 qtrssince 2022-Q1 | Unchanged 0 |
KYMERA THERAPEUTICS INC | 3.9M | $96.1M | 1.4% | $29.78 | -16.19% | 6 qtrssince 2021-Q3 | Increased 73 |
DICE THERAPEUTICS INC | 2.5M | $78.8M | 1.2% | — | — | 6 qtrssince 2021-Q3 | Increased 77 |
SYNDAX PHARMACEUTICALS INC | 2.7M | $67.4M | 1.0% | $21.64 | +17.63% | 9 qtrssince 2020-Q4 | Increased 56 |
CYMABAY THERAPEUTICS INC | 10.3M | $64.6M | 1.0% | — | — | 16 qtrssince 2019-Q1 | Unchanged 0 |
Avoro Capital Advisors LLC manages $6.7B across 36 positions as of Q4 2022. Top holdings: UTHR (11.9%), HZNP (11.9%), APLS (8.2%). Fund DNA: Balanced Allocator. HoldingsIntel Rating: 1.5/5.0.
Exited 3, increased 16, trimmed 4. Top move: HZNP (INCREASED, conviction 81). Portfolio: $6.7B across 36 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer